- Evaxion Biotech A/S (NASDAQ:EVAX) presented clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting.
- The Phase 1 trial successfully met primary endpoints for the safety and tolerability of EVX-01 in metastatic melanoma patients and demonstrated positive clinical responses in 8 out of 12 (67%) treated patients.
- Also Read: Evaxion Biotech Says Personalized Cancer Immunotherapy Meets Primary Endpoint In Melanoma Patients.
- In addition, Evaxion’s proprietary AI technology PIONEER was able to identify high-quality cancer vaccine targets, so-called neoantigens, associated with longer progression-free survival.
- The study demonstrated the ability of the PIONEER platform to identify vaccine targets associated with improved patient outcomes.
- Stratification based on PIONEER scores outperformed tumor mutational burden as a predictive biomarker, with patients having high-quality neoantigens showing better treatment responses and longer progression-free survival.
- The evaluation of treatment-related immune responses revealed strong neoantigen T-cell responses in all 12 patients, mediated by activated CD4+ T cells in all cases and CD8+ T cells in 7 out of 12 patients.
- Further, immune response magnitude correlated with the vaccination dose.
- Price Action: EVAX shares are up 10.80% at $1.64 on the last check Monday.
Cantor Fitzgerald Initiates Coverage On Verano Holdings with Overweight Rating, Announces Price Target of $10
Cantor Fitzgerald analyst Pablo Zuanic initiates coverage on Verano Holdings (OTC:VRNOF) with a Overweight rating and announces Price Target of $10.
